Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Implementation and Evaluation of SCIPI: A Multi-Site Pilot Randomized Controlled Trial to Improve Decision-Making and Quality of Life Among Patients with Localized Prostate Cancer
Study Type: Other
Phase: N/A
NCTID: NCT07280897
Principal Investigator:
William Parker
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium 177Lu vipivotide tetraxetan AAA617 versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen PSMA positive Oligometastatic Prostate Cancer OMPC
Study Type: Treatment
Phase: III
NCTID: NCT05939414
Principal Investigator:
Xinglei Shen
PSMAcTION: A phase II/III, open-label, international, multicenter, randomized study of AAA817 versus standard of care in the treatment of adult participants with PSMA-positive metastatic castration-resistant prostate cancer who progressed on or after [177Lu]Lu-PSMA targeted therapy.
Study Type: Treatment
Phase: II/III
NCTID: NCT06780670
Principal Investigator:
Xinglei Shen
An Open-Label, Multicenter Phase 1/2 Study to Evaluate the Safety and Efficacy of AB-3028 in Patients with Castration Resistant Prostate Cancer CRPC
Study Type: Treatment
Phase: I/II
NCTID: NCT07285694
Principal Investigator:
Saqib Abbasi
Quantifying Optimal Relugolix Duration with Radiation in High Risk Prostate Cancer QURE-PC
Study Type: Treatment
Phase: II
NCTID: NCT06129851
Principal Investigator:
Xinglei Shen
High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients
Study Type: Supportive Care
Phase: III
NCTID: NCT05838716
Principal Investigator:
Elizabeth Wulff
Phase 2 randomized Total Eradication of metastatic lesions following definitive Radiation to the Prostate in de novo oligometaStatic prostate cancer TERPS trial
Study Type: Treatment
Phase: II
NCTID: NCT05223803
Principal Investigator:
Xinglei Shen
A Phase III, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator?s Choice in Participants with Chemotherapy-na�ve Metastatic Castration-resistant Prostate Cancer
Study Type: Treatment
Phase: III
NCTID: NCT07213674
Principal Investigator:
Haoran Li
AcTFirst: A phase III, open-label, multi-center, randomized study comparing AAA817+ARPI versus standard of care in adult participants with PSMA-positive metastatic castration resistant prostate cancer
Study Type: Treatment
Phase: III
NCTID: NCT06855277
Principal Investigator:
Xinglei Shen
A Phase 2 Open-label Extension Study for Subjects with Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study ICON study number: 0798/0661
Study Type: Treatment
Phase: II
NCTID: NCT02960022
Principal Investigator:
Rahul Parikh